Journal of Internal Medicine Concepts & Practice >
Two cases of staged treatment of non-small cell lung cancer with traditional Chinese medicine
Received date: 2024-03-19
Online published: 2025-04-30
Lung cancer is one of the malignant tumors with the highest incidence and mortality rates globally. The prognosis of advanced lung cancer is poor, and drug resistance and toxic side effects limit clinical efficacy on it, and new treatment strategies are urgently needed. Traditional Chinese medicine (TCM) regards lung cancer as “lung accumulation”,which belonging to “general deficiency and local excess”, and the treatment emphasizes strengthening the body and eliminating pathogens. The TCM treatment of lung cancer is divided into three phases: postoperative support and nurturing, TCM combined with chemotherapy to enhance efficacy and reduce toxicity, and prevention of recurrence and metastasis. Based on this, professor Fang Zhihong mentioned that lung cancer was fundamentally characterized as deficiency of both qi and yin, with symptoms of qi stagnation, blood stasis, phlegm coagulation and toxin accumulation. He advocated the ideas of combination of disease differentiation, syndrome differentiation, and stage differentiation during the disease treatment, emphasized strengthening the spleen and stomach, cultivate righteous qi, and eliminating evil toxins. This article presents two case studies demonstrating the effectiveness of individualized staged treatment with TCM. Case 1 (stage Ⅲ B) was treated with TCM to strengthen body and eliminate pathogens after receiving targeted therapy and chemotherapy. The lesion had been stable for nearly 3 years and a total survival time was nearly 6 years; Case 2 (stage Ⅱ A) underwent postoperative TCM-assisted chemotherapy, and the survival time exceeded 8 years, and achieved clinical cure. The therapeutic effect was significant in 2 cases after using TCM methods to tonify qi and nourish yin, clear heat and detoxify, strengthen the spleen and resolve phlegm.
CHENG Dongfeng , ZHOU Ziyi , XU Rongzhong , FANG Zhihong . Two cases of staged treatment of non-small cell lung cancer with traditional Chinese medicine[J]. Journal of Internal Medicine Concepts & Practice, 2025 , 20(01) : 30 -33 . DOI: 10.16138/j.1673-6087.2025.01.06
| [1] | Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1):17-48. |
| [2] | Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53. |
| [3] | Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc, 2019, 94(8):1623-1640. |
| [4] | Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer[J]. Nat Rev Dis Primers, 2024, 10(1):71. |
| [5] | Meyer ML, Fitzgerald BG, Paz-Ares L, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer[J]. Lancet, 2024, 404(10454):803-822. |
| [6] | 刘嘉湘. 中医药治疗肺癌研究思路和临床经验[J]. 世界中医药, 2007, 2(2):67-70. |
| [7] | 龚亚斌, 折哲, 郑桥, 等. 中医药分阶段治疗肺癌的思路[J]. 世界中西医结合杂志, 2015(3):409-412. |
| [8] | 方志红, 李雁, 徐静, 等. 扶正祛邪方联合化疗治疗45例晚期非小细胞肺癌临床观察[J]. 辽宁中医杂志, 2013, 40(12):2498-2500. |
| [9] | 方志红, 李雁, 李天苗. 扶正祛邪方联合化疗治疗晚期非小细胞肺癌疗效分析[J]. 时珍国医国药, 2013, 24(10):2433-2434. |
| [10] | 方志红, 李天苗, 詹迎江, 等. 中医药干预对非小细胞肺癌患者生存期影响的回顾性分析[J]. 时珍国医国药, 2017, 28(7):1676-1678. |
/
| 〈 |
|
〉 |